CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | 7.85 |
| FCF Yield | -783.24% | -1,749.91% | -87.78% | -4.12% |
| EV / EBITDA | 2.97 | 4.94 | 2.13 | -39.99 |
| Quality | ||||
| ROIC | -32.73% | -18.19% | -38.80% | -49.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 2.25 | 0.75 | 1.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 59.31% | -64.82% | 40.79% | 19.48% |
| Safety | ||||
| Net Debt / EBITDA | 3.06 | 5.07 | 2.99 | 1.93 |
| Interest Coverage | -1,537.52 | -575.72 | -698.72 | -1,153.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -248,994.49 | -103,089.07 | -210,151.64 | -200,856.24 |